Guggenheim Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH)

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a note issued to investors on Wednesday,Benzinga reports. They presently have a $84.00 price target on the stock. Guggenheim’s target price suggests a potential upside of 294.74% from the stock’s previous close.

DNTH has been the topic of a number of other research reports. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a report on Wednesday. Finally, TD Cowen assumed coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating on the stock. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $52.14.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH opened at $21.28 on Wednesday. The firm has a market cap of $629.82 million, a price-to-earnings ratio of -8.51 and a beta of 1.82. The stock’s fifty day moving average price is $22.65 and its two-hundred day moving average price is $24.94. Dianthus Therapeutics has a one year low of $18.13 and a one year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. On average, equities analysts anticipate that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of DNTH. Quest Partners LLC lifted its position in shares of Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after buying an additional 1,124 shares during the last quarter. R Squared Ltd acquired a new position in Dianthus Therapeutics during the fourth quarter worth about $26,000. KLP Kapitalforvaltning AS bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth about $33,000. KBC Group NV acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at approximately $35,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at approximately $59,000. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.